For Research Use Only VPS34 inhibitor 1 (Compound 19, PIK-III analogue)



www.ptgcn.com

Catalog Number: CM14279

产品信息	Catalog Number: CM14279 CAS号: 1383716-46-8 分子式: C ₂₁ H ₂₅ N ₇ O 主要靶点: PI3K 主要通路: PI3K/Akt/mTOR 信号通路	分子量: 391.47 溶解度: DMSO:78 mg/mL (199.25 mM)	
靶点活性	VPS34:15 nM		
体外活性	VPS34 inhibitor 1 (Compound 19, PIK-III ar of compound 19 to prevent the degradation In addition, treatment of cells with compo previous reports using PIK-III.	n of autophagy substrates p62, NCOA4, NB	R1, NDP52, and FTH1 is similar to PIK-III.
体内活性	The pharmacokinetic profile of analogue 1 compound is rapidly absorbed and showed blood flow), with good oral bioavailability constitutes a suitable candidate for in vivo for 7 days, LC3-II accumulates consistent w in vivo.	moderate mean systemic clearance (30 n $(F\% = 47)$). Based on these PK parameters studies. Upon oral administration of com	nL/min/kg, approximately 33% of hepatic and the cellular activity, compound 19 pound 19 at 50 mg/kg twice a day (BID)
动物实验	Animal Models: C57BL/6 Mice. Formul Administration: oral administration o	ation: PG (20% v/v). Dosages: 10 mg vr I.V.	/kg(p.o.) or 2 mg/kg(I.V.)
细胞实验	Cell lines: U2OS cells.Concentrations are plated and the following day whe vehicle) or the indicated concentrati cells are lysed in RIPA supplemented passage through a Qiashredder colur	n cells had reached 90%, are treated on of PIK-III or Compound 19, both di with 1% SDS and mini-EDTA proteas	d with dimethyl sulfoxide (DMSO, issolved in DMSO. 24 hours later, se inhibitors, homogenized by
储存	Powder: -20°C for 3 years In solvent	-80°C for 1 year Shipping with blue	e ice.